The cost of delay: foregone public expenditure savings from delayed adalimumab biosimilar listing in Australia's Pharmaceutical Benefits Scheme.
- DOI
- 10.1080/14712598.2026.2746447
- Published
- 2026 Nov
- Container
- Expert opinion on biological therapy
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1080/14712598.2026.2746447,
title = {The cost of delay: foregone public expenditure savings from delayed adalimumab biosimilar listing in Australia's Pharmaceutical Benefits Scheme.},
author = {Yiu CH and Day RO and Raubenheimer J and Lu CY},
year = {2026},
journal = {Expert opinion on biological therapy},
doi = {10.1080/14712598.2026.2746447},
url = {https://doi.org/10.1080/14712598.2026.2746447}
}RIS
TY - JOUR TI - The cost of delay: foregone public expenditure savings from delayed adalimumab biosimilar listing in Australia's Pharmaceutical Benefits Scheme. AU - Yiu CH AU - Day RO AU - Raubenheimer J AU - Lu CY PY - 2026 JO - Expert opinion on biological therapy DO - 10.1080/14712598.2026.2746447 UR - https://doi.org/10.1080/14712598.2026.2746447 ER -
APA
CH, Y., RO, D., J, R., & CY, L. (2026). The cost of delay: foregone public expenditure savings from delayed adalimumab biosimilar listing in Australia's Pharmaceutical Benefits Scheme.. Expert opinion on biological therapy. https://doi.org/10.1080/14712598.2026.2746447
Source records
- pubmed · retrieved 2026-11-11T04:26:51.583Z